2-ethoxy-1-(1-methyl-pyrazol-4-yl)-ethanone | 1104291-93-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-ethoxy-1-(1-methyl-pyrazol-4-yl)-ethanone
• 英文别名: 2-ethoxy-1-(1-methylpyrazol-4-yl)ethanone
• CAS: 1104291-93-1
• 化学式: C₈H₁₂N₂O₂
• 分子量: 168.195
• InChiKey: RSKYWYDQICZLIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-甲基-4-碘-吡唑 、 N-methoxy-N-methyl-2-ethoxyacetamide 在 异丙基氯化镁 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成 2-ethoxy-1-(1-methyl-pyrazol-4-yl)-ethanone
  参考文献：
  名称：

  [EN] TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS
  [FR] DÉRIVÉS DE LA BÊTA CARBOLINE TRIAZOLE CONSTITUANT DES COMPOSÉS ANTIDIABÉTIQUES

  摘要：

  结构式(I)的β-咔啉衍生物是生长抑素亚型受体3 (SSTR3)的选择性拮抗剂，可用于治疗2型糖尿病以及通常与该疾病相关的病症，包括高血糖、胰岛素抵抗、肥胖、脂质紊乱和高血压。这些化合物还可用于治疗抑郁症和焦虑症。

  公开号：

  WO2010051177A1

文献信息

• BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS
  申请人：Dobbelaar Peter H.

  公开号：US20100184758A1

  公开（公告）日：2010-07-22

  Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.

  结构式I的β-咔啉衍生物是生长抑素亚型受体3（SSTR3）的选择性拮抗剂，可用于治疗2型糖尿病以及通常与该疾病相关的病症，包括高血糖、胰岛素抵抗、肥胖、脂质异常和高血压。这些化合物还可用于治疗抑郁症和焦虑症。
• TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTI-DIABETIC AGENTS
  申请人：Guo Liangqin

  公开号：US20110201615A1

  公开（公告）日：2011-08-18

  Beta-carboline derivatives of structural formula (I) are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.

  结构式（I）的β-咔啉衍生物是生长抑素亚型受体3（SSTR3）的选择性拮抗剂，可用于治疗2型糖尿病以及常与该疾病相关的病症，包括高血糖、胰岛素抵抗、肥胖、脂质异常和高血压。这些化合物还可用于治疗抑郁症和焦虑症。
• Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
  申请人：Vical Incorporated

  公开号：US20020019358A1

  公开（公告）日：2002-02-14

  The present invention relates to pharmaceutical compositions and methods to improve expression of exogenous polypeptides into vertebrate cells in vivo, utilizing delivery of polynucleotides encoding such polypeptides. More particularly, the present invention provides the use of salts, in particular sodium and potassium salts of phosphate, in aqueous solution, and auxiliary agents, in particular detergents and surfactants, in pharmaceutical compositions and methods useful for direct polynucleotide-based polypeptide delivery into the cells of vertebrates.

  本发明涉及利用递送编码外源多肽的多核苷酸来改善外源多肽在体内脊椎动物细胞中表达的药物组合物和方法。更具体地说，本发明提供了在药物组合物和方法中使用水溶液中的盐，特别是磷酸盐的钠盐和钾盐，以及辅助剂，特别是洗涤剂和表面活性剂，这些药物组合物和方法有助于将基于多核苷酸的多肽直接递送到脊椎动物的细胞中。
• Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
  申请人：Vical Incorporated

  公开号：US20030091544A1

  公开（公告）日：2003-05-15

  The present invention relates to methods of treating an autoimmune disease or an inflammatory condition, and in particular multiple sclerosis, in a mammal comprising administering a therapeutically effective amount of a non-infectious, non-integrating polynucleotide construct encoding a &bgr; interferon or an active fragment or variant thereof, wherein said construct is not associated with transfection-facilitating viral particles, liposomal formulations, or charged lipids.

  本发明涉及在哺乳动物中治疗自身免疫性疾病或炎症，特别是多发性硬化症的方法，包括施用治疗有效量的编码&bgr;干扰素或其活性片段或变体的非感染性、非整合性多核苷酸构建体，其中所述构建体与促进转染的病毒颗粒、脂质体制剂或带电脂质无关。
• Homogeneous enzyme immunoassay for simultaneous detection of multiple analytes
  申请人：Lin-Zhi International Inc.

  公开号：US20030224373A1

  公开（公告）日：2003-12-04

  Methods and kits are provided for the simultaneous detection of multiple analytes, i.e. to the determination of whether one or more of a plurality of analytes is present in a sample, particularly the plurality of analytes are structurally unrelated or significantly different, particularly to whether one or more of such analytes is present in a sample in a concentration that is above a predetermined minimum or cutoff value, and particularly for such analytes with different cutoffs. The methods and kits are particularly useful for-screening for the presence of a plurality of drugs (licit and/or illicit), performance-enhancing substances, and other chemicals, and involve a competitive enzyme immunoassay employing one or more conjugates of G6PDH with a plurality of the analytes.

  本发明提供了同时检测多种分析物的方法和试剂盒，即确定样品中是否存在多种分析物中的一种或多种，特别是多种分析物结构上不相关或有显著差异，特别是确定样品中是否存在浓度高于预定最小值或临界值的一种或多种分析物，特别是确定具有不同临界值的分析物。这些方法和试剂盒特别适用于筛查多种药物（合法和/或非法）、提高成绩的物质和其他化学物质的存在，并涉及一种竞争性酶免疫测定法，采用一种或多种 G6PDH 与多种分析物的共轭物。